Donepezil Hydrochloride
Product Images NDC 69150-415

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 69150-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biomes Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil Hydrochloride Structural Formula (Image 01)

Chemical structure of Donepezil Hydrochloride depicting its molecular arrangement with labeled atoms and bonds, including methoxy groups and hydrochloride moiety.*

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Image 02)

A line graph depicting ADAS-cog mean change from baseline with standard error bars over 30 weeks of drug treatment and placebo period. The graph compares three groups: Donepezil HCl 10 mg/day, Donepezil HCl 5 mg/day, and placebo, showing trends of clinical improvement and decline over time.*

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Image 03)

A cumulative percentage plot showing patients' change from baseline on the ADAS-cog scale. The graph compares Donepezil Hydrochloride 10 mg/day and 5 mg/day doses with placebo, illustrating cognitive change over treatment groups with corresponding percentages of patients achieving specific score changes.*

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 04)

A bar chart depicting patient distribution by CIBIC-plus rating, comparing Donepezil 10 mg/day, Donepezil 5 mg/day, and placebo groups. The x-axis shows response categories from Markedly Improved to Markedly Worse, while the y-axis indicates the percentage of patients in each category across treatment groups.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Image 05)

A line graph depicting the ADAS-cog mean change from baseline over 15 weeks of drug treatment comparing Donepezil HCl 10 mg/day, Donepezil HCl 5 mg/day, and placebo. The y-axis indicates clinical improvement or decline, and the x-axis shows weeks of treatment, including a placebo phase starting at week 12. Error bars representing standard error are displayed for each data point.*

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Image 06)

A cumulative percentage curve graph showing the change in ADAS-cog scores from baseline for three groups: Donepezil HCl 10 mg/day, Donepezil HCl 5 mg/day, and placebo. The vertical axis represents the cumulative percentage of patients, and the horizontal axis indicates the change from baseline, with data points labeled for 7 points, 4 points, and no change.*

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Image 07)

A bar chart comparing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, Donepezil HCl 5 mg/day, and placebo. The ratings range from markedly improved to markedly worse, showing patient distribution across each improvement or worsening level.*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Image 08)

A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil HCl 10 mg/day with placebo. The y-axis represents the mean change from baseline with standard error bars, and the x-axis shows time in months. The graph indicates clinical improvement is associated with Donepezil HCl, while the placebo shows clinical decline.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Image 09)

A cumulative percentage of patients line graph comparing Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients. Two lines represent patients treated with Donepezil HCl 10 mg/day and those given placebo, illustrating different response distributions over the SIB change scale.*

FDA Label Image

Figure 9: Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Image 10)

A line graph comparing the ADCS-ADL change from baseline over 6 months of drug treatment between Donepezil Hydrochloride 10 mg/day and placebo. The y-axis represents the mean change with standard error, showing trends of clinical improvement or decline, while the x-axis represents months of drug treatment.*

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Image 11)

A line graph comparing the cumulative percentage of patients receiving Donepezil Hydrochloride 10 mg/day versus placebo, plotted against ADCS-ADL change from baseline. The x-axis represents changes from -20 to 20, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two curves are shown, one for Donepezil HCl and one for placebo.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Image 12)

A line graph showing SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows SIB change with labels for clinical improvement, baseline, and clinical decline. The 23 mg/day dose shows greater improvement compared to the 10 mg/day dose.*

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Image 13)

A cumulative percentage of patients graph depicting the SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. The x-axis represents the SIB change from baseline, and the y-axis indicates cumulative patient percentages, illustrating patient response distributions for both dosages.*

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 14)

A bar chart comparing the percentage of patients rated by CIBIC-plus when treated with Donepezil Hydrochloride at doses of 23 mg/day and 10 mg/day. The categories range from markedly improved to markedly worse, showing distribution across these patient outcomes for both dosage groups.*

FDA Label Image

Image Description (Spl Image Label 10mg)

Donepezil Hydrochloride tablet label showing 10 mg strength, distributed by Biomes Pharmaceuticals LLC. The label states the active ingredient is Donepezil Hydrochloride USP 10 mg per tablet and includes storage instructions at controlled room temperature (20 to 25°C). The package contains 30 tablets and is marked RX only. The label includes a barcode and placeholders for lot number and expiration date.*

FDA Label Image

Donepezil Hydrochloride Tablets 23 mg Bottle Label (Spl Image Label 5mg)

Label for Donepezil Hydrochloride 5 mg tablets by Biomes Pharmaceuticals LLC. The label shows the drug name, strength, dosage form, quantity (30 tablets), storage instructions (20°C to 25°C), and manufacturer information in Lansing, MI. It includes a barcode and placeholders for lot and expiration dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.